ATE551344T1 - Neue pyrroloä2,3-aücarbazole und deren verwendung als inhibitoren von pim-kinase - Google Patents

Neue pyrroloä2,3-aücarbazole und deren verwendung als inhibitoren von pim-kinase

Info

Publication number
ATE551344T1
ATE551344T1 AT09772661T AT09772661T ATE551344T1 AT E551344 T1 ATE551344 T1 AT E551344T1 AT 09772661 T AT09772661 T AT 09772661T AT 09772661 T AT09772661 T AT 09772661T AT E551344 T1 ATE551344 T1 AT E551344T1
Authority
AT
Austria
Prior art keywords
inhibitors
pyrroloä2
aucarbazoles
new
pim kinase
Prior art date
Application number
AT09772661T
Other languages
English (en)
Inventor
Fabrice Anizon
Pascale Moreau
Michelle Prudhomme
Philip Cohen
Bettina Aboab
Rufine Akue-Gedu
Emilie Rossignol
Original Assignee
Centre Nat Rech Scient
Univ Blaise Pascal Clermont Ferrand Ii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Univ Blaise Pascal Clermont Ferrand Ii filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE551344T1 publication Critical patent/ATE551344T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT09772661T 2008-07-03 2009-06-25 Neue pyrroloä2,3-aücarbazole und deren verwendung als inhibitoren von pim-kinase ATE551344T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803752A FR2933409B1 (fr) 2008-07-03 2008-07-03 NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
PCT/FR2009/000788 WO2010000978A1 (fr) 2008-07-03 2009-06-25 NOUVEAUX PYRROLO [2,3-a] CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM

Publications (1)

Publication Number Publication Date
ATE551344T1 true ATE551344T1 (de) 2012-04-15

Family

ID=40328682

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09772661T ATE551344T1 (de) 2008-07-03 2009-06-25 Neue pyrroloä2,3-aücarbazole und deren verwendung als inhibitoren von pim-kinase

Country Status (7)

Country Link
US (1) US8481586B2 (de)
EP (1) EP2326649B1 (de)
JP (1) JP5663476B2 (de)
AT (1) ATE551344T1 (de)
CA (1) CA2729690A1 (de)
FR (1) FR2933409B1 (de)
WO (1) WO2010000978A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI630207B (zh) 2005-12-13 2018-07-21 英塞特控股公司 作為傑納斯激酶（ＪＡＮＵＳ ＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
EP3070090B1 (de) 2007-06-13 2018-12-12 Incyte Holdings Corporation Verwendung der salze des janus-kinasehemmers (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropannitril
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
EP3643312A1 (de) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octan- oder heptannitril als jak-inhibitoren
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
EP3050882B1 (de) 2010-03-10 2018-01-31 Incyte Holdings Corporation Piperidin-4-yl-azetidin-derivate als jak1-inhibitoren
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103415515B (zh) 2010-11-19 2015-08-26 因塞特公司 作为jak抑制剂的环丁基取代的吡咯并吡啶和吡咯并嘧啶衍生物
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
KR101488565B1 (ko) * 2011-12-07 2015-02-03 주식회사 두산 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR101537436B1 (ko) * 2012-08-17 2015-07-17 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
KR101452579B1 (ko) 2012-08-17 2014-10-21 주식회사 두산 신규 화합물 및 이를 포함하는 유기 전계 발광 소자
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
CA2897200C (en) 2013-01-14 2021-07-06 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
CN105189509B (zh) 2013-03-06 2017-12-19 因赛特公司 用于制备jak抑制剂的方法及中间体
SG10201912203XA (en) 2013-08-07 2020-02-27 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
CN105658653A (zh) 2013-08-23 2016-06-08 因赛特公司 可用作pim激酶抑制剂的呋喃并-和噻吩并-吡啶甲酰胺化合物
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
EP3746429B1 (de) 2018-01-30 2022-03-09 Incyte Corporation Verfahren zur herstellung von (1-(3-fluor-2-trifluormethyl)isonicotinyl)piperidin-4-on)
PT3773593T (pt) 2018-03-30 2024-06-25 Incyte Corp Tratamento da hidradenite supurativa com inibidores de jak
CN117959303A (zh) 2018-04-13 2024-05-03 住友制药肿瘤公司 用于治疗骨髓增殖性肿瘤和与癌症相关的纤维化的pim激酶抑制剂
NZ778055A (en) 2019-02-12 2025-11-28 Sumitomo Pharma America Inc Formulations comprising heterocyclic protein kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4611753A1 (de) 2022-10-31 2025-09-10 Sumitomo Pharma America, Inc. Pim1-inhibitor zur behandlung von myeloproliferativen neoplasmen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057979A1 (es) * 2005-10-06 2008-01-09 Schering Corp PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS.
WO2007058942A2 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors

Also Published As

Publication number Publication date
CA2729690A1 (fr) 2010-01-07
FR2933409A1 (fr) 2010-01-08
JP5663476B2 (ja) 2015-02-04
US8481586B2 (en) 2013-07-09
EP2326649B1 (de) 2012-03-28
EP2326649A1 (de) 2011-06-01
US20110263669A1 (en) 2011-10-27
JP2011526610A (ja) 2011-10-13
WO2010000978A1 (fr) 2010-01-07
FR2933409B1 (fr) 2010-08-27

Similar Documents

Publication Publication Date Title
ATE551344T1 (de) Neue pyrroloä2,3-aücarbazole und deren verwendung als inhibitoren von pim-kinase
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
SMP201000104B (it) Pirrolo[2,3-D]piridine e loro uso come inibitori di tirosina chinasi
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
CR20110261A (es) COMPUESTOS PIRAZOLO[1,5-a]PIRIMIDINA SUSTITUIDA COMO IHNIBIDORES DE TRK CINASA
EA201200951A1 (ru) Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения
EA201071320A1 (ru) Активаторы глюкокиназы
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
BRPI1006602A2 (pt) composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2010005876A3 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
SI2252597T1 (sl) Derivati pirazina in njihova uporaba kot inhibitorji protein kinaze
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
MX2009001494A (es) 2-aminobenzoxazol carboxamidas como moduladores 5ht3.
MX2010007927A (es) Derivados de 4-(pirrolo[2,3-c]piridin-3-il)pirimidin-2-ilamina.
UA96994C2 (ru) Производные 7-алкинил-1,8-нафтиридонов, способ их получения и их применения в терапии
MX2009002842A (es) Inhibidores heterociclicos de c-met y usos de los mismos.
ZA201003352B (en) Heterocyclic derivatives as modulators of ion channels
ATE502935T1 (de) C-met-proteinkinasehemmer
TW200730513A (en) Carbamoylbenzotriazole derivatives as inhibitors of lipases and phospholipases
ATE548035T1 (de) Formulierungen zur behandlung von lipoprotein- anormalitäten mit einem statin- und einem methylnicotinamid-derivat
ATE487721T1 (de) Triaza-benzoäeüazulenderivate zur behandlung von tumoren